| Previous Close | 166.59 |
| Open | 165.84 |
| Bid | 165.66 x 800 |
| Ask | 165.68 x 1200 |
| Day's Range | 165.01 - 166.19 |
| 52 Week Range | 133.65 - 173.65 |
| Volume | 979,303 |
| Avg. Volume | 8,300,398 |
| Market Cap | 435.016B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | 29.19 |
| EPS (TTM) | 5.66 |
| Earnings Date | Jul. 21, 2021 |
| Forward Dividend & Yield | 4.24 (2.55%) |
| Ex-Dividend Date | May 24, 2021 |
| 1y Target Est | 185.88 |
- Editor's PickYahoo Finance Video
Pfizer identifies fake COVID-19 shots abroad
Emergency Medicine Physician Dr. Hiral Tipirneni joined Yahoo Finance Live to break down how Pfizer indentified fake COVID-19 shots abroad and what this means for vaccine rollout.
- Editor's PickYahoo Finance Video
EU says J&J vaccine benefits outweigh risks, Pfizer finds fake COVID-19 shotsÂ
European regulators find a possible blood clot link with the Johnson & Johnson vaccine, but say its benefits outweigh the risks. Meanwhile, Pfizer identifies fake COVID-19 shots abroad as criminals exploit vaccine demand. Anjalee Khemlani breaks down the latest on the vaccine front.
- Reuters
India to expand vaccinations but supplies tight, imports delayed
Under fire for his handling of the world's worst COVID-19 surge, Indian Prime Minister Narendra Modi has opened vaccinations for all adults from next month, but supplies are already running short. Public forecasts by its only two vaccine producers show their total monthly output of 70-80 million doses will increase only in two months or more, though the number of people eligible for vaccines will double to an estimated 800 million from May 1. India could start receiving the Sputnik V vaccine only by end-May, its local distributor Dr. Reddy's Laboratories told Reuters, at least a month later than New Delhi had expected.
